Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsImmunogenicity refers to the trait of a drug that stimulates the body to form a line of antibodies or sensitized lymphocytes. Evaluation of immunogenicity in preclinical and clinical trials is an important part of biopharmaceuticals. Anti-drug antibodies (ADA) produced after administration may neutralize drug activity, affect drug clearance, plasma half-life, and tissue distribution, and alter pharmacodynamic (PD)/pharmacokinetic (PK) characteristics. Therefore, it is necessary to examine the immunogenicity when evaluating drug safety. Creative Biolabs owns state-of-the-art testing equipment and technology to provide you with the most accurate data on immunogenicity testing.
The ADA method may affect the test results and experimental data by potential interference during the measurement. In actual testing, the interference of this potential experimental data may result from the use of a proxy ADA when testing samples. The choice of an alternative positive control is challenging because no antibody can produce a positive response to all variants of ADA in preclinical studies. The affinity, specificity, and concentration of each antibody will vary. Corresponding in vivo polyclonal reactions can also result in multiple antibodies that react differently. Some of the positive controls used by the proxy ADA are antibodies that have been purified and can be used to stimulate normal serum to cause a positive QC peak in the expected ADA serum. Antibodies can be collected from purified antibodies, or hyperimmune animals and preclinical or clinical trials. From the hyperimmune serum, the ADA positive serum can be identified.
Fig.1 Schematic of NanoLuc bridging immunoassay. (Nath, 2017)
The generation of antibody class diversity requires not only a combination of multiple analytical methods and platform technologies, but also an increasing demand for the development and validation of accurate and robust bioanalytical methods, and requires that the resulting data stand up to regulatory review. Creative Biolabs owns comprehensive technical information and experimental experience. Please contact us as soon as possible for more information and we will be glad to serve you.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
